Valve-in-Valve with Self-Expanding Prosthesis: What Happens with Gradients at One Year?

Degenerated surgical bioprostheses can be safely treated with CoreValve or CoreValve Evolut using the valve-in-valve procedure. Excellent 1-year clinical and hemodynamic outcomes were achieved in a non-selected regular population, i.e., “real-world” patients.

valve in valve

The VIVA (Valve in Valve) registry, conducted at 23 sites, was a prospective study designed to systematically collect data from patients with degenerated surgical prostheses who underwent transcatheter aortic valve replacement.

Researchers enrolled a total of 202 patients with degenerated surgical prostheses who were eligible for elective treatment with CoreValve or CoreValve Evolut R.


Read also: Aspirin in Primary Prevention: Another “Trendy” Topic in Publications.


Mean patient age was 79.9 years old and the risk according to the Society of Thoracic Surgeons score was 6.6%.

Although 41.8% of patients had ≤21-mm surgical bioprostheses, valve hemodynamic parameters markedly improved from baseline (mean baseline valve gradient 35.0 ± 16.3 mmHg vs. 17.5 ± 8.6 mmHg at discharge). At 1 year, aortic regurgitation greater than mild was barely 1.1%.

Clinical events at 30 days demonstrated low mortality (2.5%), no disabling strokes, a 0.5% rate of acute kidney injury, and an 8% rate of permanent pacemaker implantation.

At 1 year, the mortality rate remained low (8.8%), with only 1 disabling stroke during that period (0.6%).


Read also: Pulmonary Hypertension: No Reason for TAVR Contraindication.


About 2.5% of patients (n = 5) experienced coronary artery occlusion as complication (one of the most feared for valve-in-valve); 3 took place during release, 1 immediately after the procedure, and only 1 several months later.

Conclusion

Surgically-implanted valves with bioprosthetic degeneration can be safely treated with the self-expanding device with more evidence in the market, which has excellent 1-year clinical and hemodynamic outcomes in this real-world non-selected population.

Orginal Title: TAVR for Failed Surgical Aortic Bioprostheses Using aSelf-Expanding Device 1-Year Results From the Prospective VIVA Postmarket Study.

Reference: Didier Tchétché et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...